Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Low levels of selenoprotein P associate with cognitive impairment in patients hospitalized for heart failure

Jujic, Amra LU ; Molvin, John LU ; Nilsson, Erik D. LU ; Holm Isholth, Hannes LU ; Dieden, Anna LU orcid ; Korduner, Johan LU ; Zaghi, Amir LU orcid ; Nezami, Zainu LU ; Bergmann, Andreas and Schomburg, Lutz , et al. (2024) In Journal of Cardiac Failure
Abstract
Background
Selenoprotein P (SELENOP) is a transporter for selenium and has been shown to protect selenium status maintenance in brain against deficiency, supporting neuronal development, neurogenesis and neurocognitive function. Selenium deficiency has previously been associated with cognitive impairment in various populations, but no studies have been carried out in subjects with heart failure (HF).
Purpose
To explore if SELENOP deficiency in subjects with acute HF is associated with cognitive impairment.
Methods
Plasma SELENOP measured through an immunoassay analysis is a well-validated marker of plasma selenium status with the benefit of providing information on the bioavailable fraction of selenium to preferentially... (More)
Background
Selenoprotein P (SELENOP) is a transporter for selenium and has been shown to protect selenium status maintenance in brain against deficiency, supporting neuronal development, neurogenesis and neurocognitive function. Selenium deficiency has previously been associated with cognitive impairment in various populations, but no studies have been carried out in subjects with heart failure (HF).
Purpose
To explore if SELENOP deficiency in subjects with acute HF is associated with cognitive impairment.
Methods
Plasma SELENOP measured through an immunoassay analysis is a well-validated marker of plasma selenium status with the benefit of providing information on the bioavailable fraction of selenium to preferentially supplied cells equipped with receptors for SELENOP uptake. SELENOP was measured in 320 subjects hospitalized for HF. One-hundred-eighty-seven of the subjects also underwent four cognitive tests assessing global cognitive function [Montreal Cognitive Assessment (MoCA)], information processing [Symbol Digit Modalities Test (SDMT)], visual attention and task switching [Trailmaking Test A (TMT-A)], and executive speed [A Quick Test of Cognitive Speed (AQT) form and color]. Appropriate cut-offs were used for each cognitive test to define cognitive impairment. Cross-sectional associations between SELENOP concentrations and cognitive impairment defined by each cognitive test were explored using multivariable logistic models. Further, multivariable logistic models exploring associations between selenium deficiency defined as the lowest quartile of SELENOP levels and cognitive impairment defined by each cognitive test were carried out.
Results
The 187 participants had a mean age 73 (±11.9) years; 31% were female, with a mean BMI of 28.1 (±5.6) kg/m2. Each 1 SD increment in SELENOP-concentrations was associated with lower odds of cognitive impairment defined as MoCA cut-off score <23 (odds ratio (OR) 0.60; 95%CI 0.40-0.91; p= 0.017). Further, SELENOP-concentrations within the lowest quartile (≤2.3 mg/L) were associated with cognitive impairment measured by MoCA (OR 3.10; 95%CI 1.38-6.97; p=0.006), SDMT (OR 2.26; 95%CI 1.10-4.67; p=0.027) and TMT-A (OR 3.40; 95%CI 1.47-7.88; p=0.004)), but not by AQT form and color.
Conclusions
In subjects admitted for heart failure, higher SELENOP concentrations were associated with better performance on the MoCA test reflecting global cognition, and SELENOP-deficiency was associated with cognitive impairment as defined by three cognitive tests. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
epub
subject
in
Journal of Cardiac Failure
publisher
Elsevier
external identifiers
  • scopus:85186073409
ISSN
1071-9164
DOI
10.1016/j.cardfail.2024.01.010
language
English
LU publication?
yes
id
02be852a-6ee0-4945-9273-b046e0d18d29
date added to LUP
2024-02-15 10:46:52
date last changed
2024-03-22 14:25:36
@article{02be852a-6ee0-4945-9273-b046e0d18d29,
  abstract     = {{Background<br/>Selenoprotein P (SELENOP) is a transporter for selenium and has been shown to protect selenium status maintenance in brain against deficiency, supporting neuronal development, neurogenesis and neurocognitive function. Selenium deficiency has previously been associated with cognitive impairment in various populations, but no studies have been carried out in subjects with heart failure (HF).<br/>Purpose<br/>To explore if SELENOP deficiency in subjects with acute HF is associated with cognitive impairment.<br/>Methods<br/>Plasma SELENOP measured through an immunoassay analysis is a well-validated marker of plasma selenium status with the benefit of providing information on the bioavailable fraction of selenium to preferentially supplied cells equipped with receptors for SELENOP uptake. SELENOP was measured in 320 subjects hospitalized for HF. One-hundred-eighty-seven of the subjects also underwent four cognitive tests assessing global cognitive function [Montreal Cognitive Assessment (MoCA)], information processing [Symbol Digit Modalities Test (SDMT)], visual attention and task switching [Trailmaking Test A (TMT-A)], and executive speed [A Quick Test of Cognitive Speed (AQT) form and color]. Appropriate cut-offs were used for each cognitive test to define cognitive impairment. Cross-sectional associations between SELENOP concentrations and cognitive impairment defined by each cognitive test were explored using multivariable logistic models. Further, multivariable logistic models exploring associations between selenium deficiency defined as the lowest quartile of SELENOP levels and cognitive impairment defined by each cognitive test were carried out.<br/>Results<br/>The 187 participants had a mean age 73 (±11.9) years; 31% were female, with a mean BMI of 28.1 (±5.6) kg/m2. Each 1 SD increment in SELENOP-concentrations was associated with lower odds of cognitive impairment defined as MoCA cut-off score &lt;23 (odds ratio (OR) 0.60; 95%CI 0.40-0.91; p= 0.017). Further, SELENOP-concentrations within the lowest quartile (≤2.3 mg/L) were associated with cognitive impairment measured by MoCA (OR 3.10; 95%CI 1.38-6.97; p=0.006), SDMT (OR 2.26; 95%CI 1.10-4.67; p=0.027) and TMT-A (OR 3.40; 95%CI 1.47-7.88; p=0.004)), but not by AQT form and color.<br/>Conclusions<br/>In subjects admitted for heart failure, higher SELENOP concentrations were associated with better performance on the MoCA test reflecting global cognition, and SELENOP-deficiency was associated with cognitive impairment as defined by three cognitive tests.}},
  author       = {{Jujic, Amra and Molvin, John and Nilsson, Erik D. and Holm Isholth, Hannes and Dieden, Anna and Korduner, Johan and Zaghi, Amir and Nezami, Zainu and Bergmann, Andreas and Schomburg, Lutz and Magnusson, Martin}},
  issn         = {{1071-9164}},
  language     = {{eng}},
  month        = {{02}},
  publisher    = {{Elsevier}},
  series       = {{Journal of Cardiac Failure}},
  title        = {{Low levels of selenoprotein P associate with cognitive impairment in patients hospitalized for heart failure}},
  url          = {{http://dx.doi.org/10.1016/j.cardfail.2024.01.010}},
  doi          = {{10.1016/j.cardfail.2024.01.010}},
  year         = {{2024}},
}